KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Working Capital Changes: 2019-2024

Historic Other Working Capital Changes for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$28.0 million.

  • Recursion Pharmaceuticals' Other Working Capital Changes fell 190.09% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.4 million, marking a year-over-year decrease of 31.07%. This contributed to the annual value of -$28.0 million for FY2024, which is 31.74% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Other Working Capital Changes of -$28.0 million as of FY2024, which was up 31.74% from -$41.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Other Working Capital Changes registered a high of $110.3 million during FY2022, and its lowest value of -$41.1 million during FY2023.
  • Its 3-year average for Other Working Capital Changes is $13.7 million, with a median of -$28.0 million in 2024.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first skyrocketed by 4,319.46% in 2020, then plummeted by 137.50% in 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' Other Working Capital Changes (Yearly) stood at $26.7 million in 2020, then plummeted by 137.50% to -$10.0 million in 2021, then soared by 1,203.20% to $110.3 million in 2022, then plummeted by 137.23% to -$41.1 million in 2023, then surged by 31.74% to -$28.0 million in 2024.